The Drugs Used in the Treatment of Supraventricular Tachycardia in Pediatrics: A Systematic Review and Meta-Analysis

IF 0.2 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Cor et vasa Pub Date : 2023-06-20 DOI:10.33678/cor.2022.097
H. T. Hashim, Jaffer Shah, Ali Talib Hashim, Omar Abdelnasser Abdelmonem Ismail Mohamed, Mahmoud Shaban Abdeljalil, J. Varney
{"title":"The Drugs Used in the Treatment of Supraventricular Tachycardia in Pediatrics: A Systematic Review and Meta-Analysis","authors":"H. T. Hashim, Jaffer Shah, Ali Talib Hashim, Omar Abdelnasser Abdelmonem Ismail Mohamed, Mahmoud Shaban Abdeljalil, J. Varney","doi":"10.33678/cor.2022.097","DOIUrl":null,"url":null,"abstract":"Background: Supraventricular tachycardia (SVT) is an abnormally rapid heart rhythm that results from improper electrical activity in the upper part of the heart. Acute management of children presenting with SVT may be a challenge, as the exact tachycardia mechanism is often unknown. The strategy for treatment depends on the presentation and clinical status of the patient. Methodology: A systematic literature review was conducted to identify and select original research reports on supraventricular tachycardia management drugs in children and infants with no structural heart disease (all children from 1 hour to 17 years of age) in accordance with the PRISMA guidelines. Data were analyzed with Review manager version 5.4. P -value and I 2 were used to test the signifi cance difference. Results: 26 studies out of 65 total studies assessed for eligibility were included in the review by fulfi lling the inclusion criteria. There were 8103 patients from 13 countries with SVT who were treated with different antiarrhythmic drugs including (Adenosine, Dexmedetomidine) as acute management and (Amiodarone, Beta-Blockers, Flecainide, Digoxin and Ivabradine) as chronic control. There was a signifi cant difference between the patients who took the drugs and the patients who responded to the drugs, with P -value <0.005 and I 2 = 72%.","PeriodicalId":10787,"journal":{"name":"Cor et vasa","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2023-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cor et vasa","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33678/cor.2022.097","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 1

Abstract

Background: Supraventricular tachycardia (SVT) is an abnormally rapid heart rhythm that results from improper electrical activity in the upper part of the heart. Acute management of children presenting with SVT may be a challenge, as the exact tachycardia mechanism is often unknown. The strategy for treatment depends on the presentation and clinical status of the patient. Methodology: A systematic literature review was conducted to identify and select original research reports on supraventricular tachycardia management drugs in children and infants with no structural heart disease (all children from 1 hour to 17 years of age) in accordance with the PRISMA guidelines. Data were analyzed with Review manager version 5.4. P -value and I 2 were used to test the signifi cance difference. Results: 26 studies out of 65 total studies assessed for eligibility were included in the review by fulfi lling the inclusion criteria. There were 8103 patients from 13 countries with SVT who were treated with different antiarrhythmic drugs including (Adenosine, Dexmedetomidine) as acute management and (Amiodarone, Beta-Blockers, Flecainide, Digoxin and Ivabradine) as chronic control. There was a signifi cant difference between the patients who took the drugs and the patients who responded to the drugs, with P -value <0.005 and I 2 = 72%.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
儿科治疗室上性心动过速的药物:系统评价和荟萃分析
背景:室上性心动过速(SVT)是一种异常快速的心律,由心脏上部不适当的电活动引起。急性处理出现室上性心动过速的儿童可能是一个挑战,因为确切的心动过速机制通常是未知的。治疗策略取决于患者的表现和临床状况。方法:根据PRISMA指南,对无结构性心脏病的儿童和婴儿(所有1小时至17岁的儿童)的室上性心动过速治疗药物进行了系统的文献综述,以确定和选择原始研究报告。使用Review manager 5.4版对数据进行分析。P值和I2用于检验显著性差异。结果:在评估合格性的65项研究中,有26项研究通过填写纳入标准纳入审查。来自13个国家的8103名SVT患者接受了不同的抗心律失常药物治疗,包括作为急性治疗的(腺苷、右美托咪定)和作为慢性对照的(胺碘酮、β-阻滞剂、Flecainide、地高辛和Ivabradine)。服用药物的患者和对药物有反应的患者之间存在显著差异,P值<0.005,I2=72%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cor et vasa
Cor et vasa CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
0.50
自引率
50.00%
发文量
66
期刊最新文献
Artificial intelligence in resting ECG: Higher accuracy in the interpretation of rhythm abnormalities (Commentary to the article The year in cardiovascular medicine 2022: the top 10 papers in heart failure and cardiomyopathies) (Use of multimodal imaging in patients with multiple ventricular extrasystoles - pilot results) (Peripheral artery disease of the legs - the current state) (The CD36 receptor - the link between inflammation, lipid metabolism, and cardiovascular disease)
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1